Abstract
Introduction
The metabolic syndrome (MetS), characterized by abdominal obesity, hyper-trigliceridaemia, low levels of high-density lipoprotein (HDL) cholesterol, hypertension and elevated fasting glucose levels [1] is a major health risk in developed countries, with a prevalence of 25% among adults in the United States [2] . MetS is associated with an increased risk for cardiovascular disease in both genders [3] . It is also perceived as signalling a pre-diabetic state [4] [5] .
since many of its features are predictors of type 2 diabetes mellitus (T2DM) and the risk for incident T2DM is up to five times higher in individuals with MetS compared to controls
T2DM, inversely, is viewed as an end-stage manifestation of MetS [6] , although the molecular mechanisms involved in this shift remain incompletely understood. Over 90% of T2DM patients show extracellular deposits adjacent to ␤ cells [7, 8] 
formed by aggregation of the islet amyloid polypeptide (IAPP, or amylin), a normal product of ␤ cells co-produced and co-secreted with insulin. Amylin is elevated in conditions associated with insulin resistance and hyper-insulinaemia such as the early stages of
T2DM, and accumulating evidence supports a role for amylin deposits in T2DM ␤-cell failure [9] [10] [11] [12] . Interestingly, a synthetic analogue of human amylin, SYMLIN ® (pramlintide acetate), is used as an adjunct to insulin therapy in both type 1 and type 2 diabetes patients [13] to facilitate improvement in glycaemic control and weight gain [14] .
Biochemical and neurophysiological measurements point to enhanced sympathetic and impaired parasympathetic functioning in MetS patients [15] . More specifically, decreased vagal activity was found in individuals with obesity [16] , dysglycaemia [17] , hypertension [18, 19] and hyperlipidaemia [20] , suggesting perturbation of cholinergic pathways in MetS. One possible cause of impaired vagal activity is the increase in butyrylcholinesterase (BChE)-mediated hydrolysis of acetylcholine (ACh) observed in early T2DM patients, followed by BChE decreases in established patients [21] . This temporary BChE elevation would reduce parasympathetic signals, increasing the sympathetic to parasympathetic ratio. [22] . We also found that a peptide derived from the C-terminal sequence of BChE-U, the 'usual' variant of the enzyme, was more potent in attenuating this oligomerization than a peptide derived from the C-terminal sequence of BChE-K, the 'Kalow' variant of the enzyme with lowered cholinesterase activity [23] . Interestingly, BChE-K has also been proposed to be a risk factor for T2DM and coronary artery disease [24, 25] 
These reported changes in BChE activity have been viewed from an enzymatic point of view. However, we recently discovered that BChE attenuates the formation of Alzheimer's disease (AD) ␤-amyloid (A␤) fibrils and protects cultured neurons from their cytotoxicity

Definition of risk factors
MetS definition was based on the National Cholesterol Education Program
Adult Treatment Panel III criteria [1] with the modified impaired fasting glucose criteria [26] as proposed by the updated American Heart Association/National Heart, Lung, and Blood Institute scientific statement [27] were used as previously reported [29, 30] .
Proteins and peptides
Recombinant human BChE (rhBChE) was produced and provided by PharmAthene (Montreal, Canada) as described [23] . Recombinant human 'read-through' AChE (rhAChE-R), the monomeric stress-induced isoform of AChE, was produced and provided by Protalix Biotherapeutics (Carmiel, Israel) [31, 32] Fig. 2A 
Photo-induced cross-linking (PICUP)
Results
MetS involves an increase in serum BChE activity
rhBChE interacts with amylin
To examine the involvement of BChE protein-peptide interactions in the shift from MetS to T2DM, we performed PICUP of highly purified rhBChE of the U variant (Fig. 3A) (Fig. 3C) , representing rhBChE Figure 3D shows that amylin (as ana- 
tetramers (~280 kD) complexed with amylin (the doublet may represent two distinct forms of these complexes), as well as an amylin hexamer band (~27 kD). Samples containing rhBChE alone showed no staining for amylin. We next used SPR to study the interaction between rhBChE and amylin. The sensorgram in
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Fig. 1 Cholinergic activity and risk factors in MetS patients. (A)-(D) Cholinergic activity (A-B, BChE; C-D, AChE) versus the number of MetS components, according to gender, represented as bar graphs Ϯ S.E.M. (0 represents individuals with no components, Ͼ3 represents individuals with four or five components). One-way ANOVA was used to compare groups, P Ͻ 0.001. (E) and (F) The interaction of triglyceride levels and waist circumference with cholinergic activity. Bar graphs represent mean cholinergic status Ϯ S.E.M. for each combination of factors, by gender (E, men; F, women). (G) and (H) BChE activity in tertiles of C-reactive protein. Bar graphs represent the mean calculated BChE activity Ϯ S.E.M., by gender (G, men; H, women).
Fig. 2 Serum BChE activities in diabetic and non-diabetic individuals of different genotypes. BChE activity was calculated as detailed in the 'Materials and methods' section, and is expressed as nmol substrate hydrolysed per minute per ml serum. Bar graphs represent the frequencies of activity, and the average activity Ϯ S.D. of each group is noted in the box. (A) Activity in diabetic and non-diabetic individuals of all three genotypes (UU, UK and KK) (diabetic
lyte) interacts with immobilized rhBChE in a dose-dependent manner. This interaction could occur through the core domain of BChE, similar to the interaction of the synaptic AChE (AChE-S)
with the amyloidogenic peptide A␤ [36] . Alternatively, it could involve its C-terminal area, similar to the interaction of the 'readthrough' variant AChE-R and BChE with A␤ [22, 23, 37] . To distinguish between these possibilities we studied the interaction of amylin (as analyte) with the immobilized C-terminal peptides BChE-U and BChE-K (Fig. 3B) , as well as immobilized amylin. The resultant sensorgrams revealed dose-dependent amylin-amylin interactions (Fig. 3E) , but neither BSP-U nor BSP-K interacted with amylin ( Fig. 3F and G) . We therefore attribute the observed amylin interaction to the core domain of rhBChE. The SPR measurements also revealed a dose-dependent interaction between amylin and AChE-R (Fig. 3H) .
rhBChE attenuates the aggregation of amylin
The similar amyloidogenic properties of amylin and A␤ [38] together with our previous findings that AChE-R can attenuate A␤ fibril formation in vivo [37] raised the possibility that rhBChE can similarly attenuate the aggregation of amylin. We therefore used the ThT fluorescence assay to measure the aggregation of amylin in the absence and presence of rhBChE. As shown in Figure 4A , amylin alone yielded a sigmoidal fluorescence time curve, consistent with the presence of lag, elongation and saturation phases in the fibril formation process, and in agreement with previous reports [10, 39] [40, 41] . In addition, blockade of LOX expression can protect cortical neurons from A␤-induced apoptosis [42] and knockout of LOX in mice can prevent cytokine-induced pancreatic ␤-cell dysfunction [43] . Intriguingly, as shown in Figure 4B, Fig. 4C and D 
LOX also inhibited the fibrillation of amylin, albeit in a less potent manner than rhBChE, with a shorter lag phase and shallower elongation curve. The synthetic BSP-U and BSP-K peptides did not attenuate amylin fibril formation at any of the concentrations used (
), indicating that in contrast to its effect on A␤, BChE attenuation of amylin oligomerization does not involve the C-terminal domain.
rhBChE attenuates the early oligomerization of amylin
ThT fluorescence signals reflect the amount of amyloid fibrils formed [44] Figure 5A , at the initial time-point (only 3-5 min. after mixing the reaction components) amylin attained several soluble forms, from monomers up to hexamers, reflecting its highly amyloidogeic nature. These soluble forms were not visible, however, at later time-points. When amylin was incubated in the presence of rhBChE it showed similar oligomeric forms at the initial timepoint, but these remained in the soluble fraction for at least 12 hrs. In comparison, when amylin was incubated with LOX (Fig. 5B) [24, [46] [47] [48] [49] [50] [51] . In our study we observed a lower incidence of the K-variant in T2DM patients compared to controls. Although we note that the difference was not statistically significant, possibly due to the small sample size, this result excludes the K-variant as a risk factor for T2DM and may even support its proposed protective effect [51] . 
monomers, then separated the resulting oligomeric complexes by SDS-PAGE and visualized them by silver staining. As can be seen in
